Eli Lilly's Mounjaro shortage worsens ahead of potential obesity FDA approval
Fierce Pharma
JULY 26, 2023
Food and Drug Administration has added a fourth dose of Lilly’s popular new diabetes med to its drug shortage database. As with Novo Nordisk’s popular offering for obesity, Wegovy, demand for Eli Lilly’s dual GIP/GLP-1 agonist Mounjaro appears to be outpacing supply once again. |
Let's personalize your content